Puma Biotechnology | PBYI - Interest Expense On Debt


Puma Biotechnology reported $3.37M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amgen USD 653M 94.99B Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Daiichi Sankyo JPY 14.13B 10.56B Sep/2026
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 269M 22M Sep/2026
Glaxosmithkline GBP 264.74M 72.01M Sep/2026
Incyte USD 605K 23K Sep/2026
MacroGenics USD 4.4M 493K Jun/2026
Moderna USD 10.96B 527M Jun/2026
Novartis USD 468M 6M Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Takeda JPY 63.38B 466M Sep/2026
TG Therapeutics USD 16.57M 8.91M Jun/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026